PMID- 37581143
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230816
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 7
DP  - 2023 Jul
TI  - Treating Iron Deficiency (ID) Anemia in Heart Failure (HF) Patients with IV Iron: 
      A Meta-Analysis.
PG  - e41895
LID - 10.7759/cureus.41895 [doi]
LID - e41895
AB  - Findings on the effects of iron on heart failure (HF) hospitalizations and 
      mortality among patients with iron deficiency (ID) and HF remain conflicting 
      across different studies. We performed a meta-analysis of clinical trials 
      assessing the clinical, hematic and cardiovascular benefits of treating ID in HF 
      patients. We completed a systematic search for studies comparing IV iron to 
      placebo in HF patients with ID. The primary outcomes were rates of HF 
      hospitalization and all-cause mortality. Secondary outcomes included change in 
      hematic values, New York Heart Association (NYHA) class and ejection fraction. We 
      applied a random-effects model with planned sensitivity analyses of studies with 
      skewed effect sizes. Nine studies were included with a total of 2,261 patients. 
      Analysis revealed that treatment of HF patients with IV iron replacement 
      significantly reduced the odds of HF hospitalization (odds ratio (OR): 0.44; 95% 
      confidence interval (CI): 0.24 to 0.78; p=0.005, I(2)=67%),) but did not 
      significantly impact all-cause mortality compared to placebo (OR: 0.89; 95%, 
      CI: 0.67 to 1.19; p=0.44, I(2): 0%). Analysis showed that IV iron treatment group 
      had significantly higher serum ferritin, transferrin saturation and hemoglobin 
      (Hb) levels. They also had lower NYHA class -1.90 (95% CI (-2.91 to -0.89); 
      p<0.001, I(2):89%) with higher ejection fraction 0.50 (95% CI (0.09 to 0.90) 
      p=0.016, I(2):86%). Treatment with IV iron in HF patients with ID is associated 
      with a significant reduction of HF hospitalization but no effects on all-cause 
      mortality. There were also significant increases in hematic values and ejection 
      fraction with a reduction in NYHA class.
CI  - Copyright (c) 2023, Ogugua et al.
FAU - Ogugua, Fredrick M
AU  - Ogugua FM
AD  - Cardiology, University of Illinois Chicago, Chicago, USA.
FAU - Aguilar, Francisco A
AU  - Aguilar FA
AD  - Internal Medicine, Einstein Medical Center Philadelphia, Philadelphia, USA.
FAU - Gamam, Abdulrahman
AU  - Gamam A
AD  - Internal Medicine, Minneapolis Heart Institute, Minneapolis, USA.
FAU - Maqsood, Muhammad Haisum
AU  - Maqsood MH
AD  - Internal Medicine, Lincoln Medical Center, New York, USA.
FAU - Yoo, Tae Kyung
AU  - Yoo TK
AD  - Medicine, MetroWest Medical Center, Framingham, USA.
FAU - Kasmi, Fedi
AU  - Kasmi F
AD  - Internal Medicine, Sheikh Khalifa Hospital, Ajman, ARE.
FAU - AlKowatli, Oubada
AU  - AlKowatli O
AD  - Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, USA.
FAU - Lo, Kevin
AU  - Lo K
AD  - Internal Medicine, Einstein Medical Center Philadelphia, Philadelphia, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230714
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10423640
OTO - NOTNLM
OT  - erythropoietin
OT  - heart failure hospitalization
OT  - hematic values
OT  - intravenous iron supplement
OT  - ischemic cardiomyopathy
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/08/15 06:42
MHDA- 2023/08/15 06:43
PMCR- 2023/07/14
CRDT- 2023/08/15 03:38
PHST- 2023/07/14 00:00 [accepted]
PHST- 2023/08/15 06:43 [medline]
PHST- 2023/08/15 06:42 [pubmed]
PHST- 2023/08/15 03:38 [entrez]
PHST- 2023/07/14 00:00 [pmc-release]
AID - 10.7759/cureus.41895 [doi]
PST - epublish
SO  - Cureus. 2023 Jul 14;15(7):e41895. doi: 10.7759/cureus.41895. eCollection 2023 
      Jul.